News
2 Green Flags and 1 Red Flag for Novartis Stock
Share prices of Swiss pharmaceutical company Novartis (NYSE: NVS) have climbed more than 10% so far this year. The company focuses on cardiovascular, immunology, neuroscience, solid tumors, and
Novartis Ag (NVS) Q3 2023 Earnings Call Transcript
2 Biotech Stocks That Could Make You Richer
Although sometimes risky and volatile, the biotech industry is an excellent place to find stocks that can generate steady returns for years. That's because these companies tend to offer products
3 Unstoppable Stocks to Buy and Hold for Decades
Want to invest in stocks that you can buy and forget about? If so, you'll want to consider companies with plenty of long-term growth opportunities and solid financials. Among the best growth
2 Dividend Stocks to Buy and Hold Forever
Finding dividend stocks worth holding onto for good isn't an easy task. Investors shouldn't necessarily rely on a company's current dividend yield to make that decision. Recent history has shown
Could This Medicine Be the Next Winner for Novartis?
Earlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug candidate remibrutinib for a skin condition known
2 Top Biotech Stocks to Buy Right Now
Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend income. The trick is diversifying across top businesses in numerous industries to
2 Stocks That Raised Their Guidance in July
One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:
Should Income Investors Buy This Blue Chip Stock?
For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an
Why Novartis Stock Spiked Today
Novartis (NYSE: NVS) enjoyed a strong rally today, as the Swiss drugmaker announced an improved revenue forecast for 2023 and a massive share repurchase program. Specifically, the drugmaker's stock
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
Why Novartis Stock Slipped on Friday
Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical
Why Shares of Vera Therapeutics Jumped Tuesday
Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to
Why Shares of Chinook Therapeutics Skyrocketed On Monday
Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis.
Chinook is a
Is Novartis a Good Stock to Buy Right Now?
Novartis (NYSE: NVS) is a company in transition. Over the past several years, the Swiss multinational pharma giant has been busy divesting key assets such as its eye care unit Alcon, trimming costs
Why Analog Devices Stock Was Down This Week
Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's
Why Shares of Rain Oncology Are Plummeting Today
Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated
Vifor Pharma nimmt Stellung zu Medienspekulationen
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor führt mit CSL Gespräche über eine mögliche Transaktion. Entsprechende Entscheide sind noch nicht gefallen, es gibt